Vir Biotechnology Inc (VIR)
Healthcare
Biotechnology
8.70 $
-2.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Vir Biotechnology Inc (VIR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.3% of the shares are freely tradable; institutional investors hold 81.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
81.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
6.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
76.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
169Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 10.67 | 17,998,329 | +10.2 | 03/31/2026 |
| ARCH VENTURE CORP | 7.66 | 12,916,663 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 7.44 | 12,548,944 | -2.0 | 12/31/2025 |
| SB INVESTMENT ADVISERS (UK) LTD | 6.49 | 10,948,093 | -16.5 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 5.46 | 9,215,577 | +0.0 | 03/31/2026 |
| GSK PLC | 5.07 | 8,550,954 | +0.0 | 03/31/2026 |
| State Street Corp | 4.23 | 7,141,094 | +14.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.19 | 5,382,103 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.06 | 6,846,876 | +0.0 | 05/29/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.36 | 3,975,748 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.